Trial
NCT04659603
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Breast Cancer Metastatic
Intervention
tusamitamab ravtansine
Why stopped
Sponsor decision, the decision is not related to any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-01